Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

NCT00095667 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: lapatinib ditosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)